| Mrs Lori Lee Landy, LCSW, SAC | |
|
W156n8327 Pilgrim Rd, 302, Menomonee Falls, WI 53051-3776 | |
| (262) 251-1112 | |
| (262) 251-1113 |
| Full Name | Mrs Lori Lee Landy |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | W156n8327 Pilgrim Rd, Menomonee Falls, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730415852 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YA0400X | Counselor - Addiction (substance Use Disorder) | 14104-131 (Wisconsin) | Secondary |
| 1041C0700X | Social Worker - Clinical | 6734-123 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Lori Lee Landy, LCSW, SAC N173w19997 Creekside Dr, Jackson, WI 53037-9107 Ph: (262) 442-2107 | Mrs Lori Lee Landy, LCSW, SAC W156n8327 Pilgrim Rd, 302, Menomonee Falls, WI 53051-3776 Ph: (262) 251-1112 |
News Archive
When people think about the management of diabetes, A1C (hemoglobin) tests and foot exams usually come to mind. Often overlooked is the recommended retinal eye exam. This eye exam is crucial because many West Virginians with diabetes are at risk for blindness caused by diabetic retinopathy.
Exposure to nicotine during development inhibits the function of neurons controlling the tongue, according to research in newborn rats recently published in eNeuro. This impairment may be a factor in sudden infant death syndrome in humans.
Despite past safety concerns, the antioxidant supplement beta-carotene, is safe to use during radiation therapy treatments for prostate cancer and does not increase the risk of prostate cancer death or metastases, according to a study in the May issue of the International Journal of Radiation Oncology•Biology•Physics, the official scientific journal of the American Society for Radiation Oncology.
In honor of World Stroke Day (October 29, 2010), Coherex Medical, Inc. today announced it has achieved two milestones that further strengthen its position as an emerging medical device company in the field of structural heart disease.
Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today announced that the U.S. Food and Drug Administration has approved its New Drug Application for Karbinal ER (carbinoxamine maleate) Extended-release Oral Suspension 4mg/5ml, the first sustained-release histamine receptor blocking agent indicated for the treatment of seasonal and perennial allergic rhinitis in children ages 2 and up.
› Verified 1 days ago